Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K
Introduction to Hemostasis01:05

Introduction to Hemostasis

7.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.7K
Coagulation01:09

Coagulation

6.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Human Evolution: Between Hemorrhage and Thrombosis.

Seminars in thrombosis and hemostasis·2026
Same author

<i>YoyoMut</i>: Interactive Exploration of SARS-CoV-2 Mutation Fixation and Reversion Through Time.

Life (Basel, Switzerland)·2026
Same author

TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses.

Vaccines·2026
Same author

On the Use of Immunoglobulins for Pre-exposure Prophylaxis Against COVID-19 in Immunocompromised Patients.

Infection and drug resistance·2026
Same author

Metabolic determinants of torque teno virus load across the diabetes spectrum: insights from a cross-sectional analysis.

Scientific reports·2026
Same author

COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval.

Expert review of anti-infective therapy·2026

Related Experiment Video

Updated: Jul 4, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.2K

Tranexamic Acid: An Evergreen Hemostatic Agent.

Massimo Franchini1, Daniele Focosi2, Pier Mannuccio Mannucci3

  • 1Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy.

Seminars in Thrombosis and Hemostasis
|February 9, 2024
PubMed
Summary

Tranexamic acid (TXA) effectively reduces blood loss by inhibiting fibrinolysis. This review highlights recent findings and applications of this antifibrinolytic agent in various medical and surgical settings.

More Related Videos

Author Spotlight: Non-Surgical Treatment of Melasma&#8211; Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

896
TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application
08:40

TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application

Published on: June 8, 2016

14.2K

Related Experiment Videos

Last Updated: Jul 4, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.2K
Author Spotlight: Non-Surgical Treatment of Melasma&#8211; Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

896
TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application
08:40

TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application

Published on: June 8, 2016

14.2K

Area of Science:

  • Pharmacology and Therapeutics
  • Hemostasis and Thrombosis
  • Surgical Research

Background:

  • Tranexamic acid (TXA) is a well-established antifibrinolytic agent.
  • It functions by inhibiting plasminogen activation and subsequent fibrinolysis.
  • TXA has a history of over 60 years of clinical use.

Purpose of the Study:

  • To review recent findings on the clinical applications of tranexamic acid.
  • To summarize current indications for TXA use.
  • To provide an updated overview of TXA research.

Main Methods:

  • Narrative review of recent scientific literature.
  • Synthesis of data from controlled randomized trials.
  • Analysis of clinical outcomes and safety data.

Main Results:

  • Consistent documentation of TXA's effectiveness in reducing blood loss.
  • Evidence supports TXA's safety across various interventions.
  • TXA remains an active area of ongoing research.

Conclusions:

  • Tranexamic acid is a proven and safe antifibrinolytic agent.
  • Recent research continues to expand its clinical indications.
  • TXA remains a critical tool in managing excessive bleeding.